Article
Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost.
Nature microbiology - 1 Nov 2024
Bédard Camille, Gagnon-Arsenault Isabelle, Boisvert Jonathan, Plante Samuel, Dubé Alexandre K, Pageau Alicia, Fijarczyk Anna, Sharma Jehoshua, Maroc Laetitia, Shapiro Rebecca S, Landry Christian R
Abstract excerpt
Azole antifungals are the main drugs used to treat fungal infections. Amino acid substitutions in the drug target Erg11 (Cyp51) are a common resistance mechanism in pathogenic yeasts. How many and which mutations confer resistance is, however, largely unknown. Here we measure the impact of nearly 4,000 amino acid variants of Candida albicans Erg11 on the susceptibility to six clinical azoles. This was achieved by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.